Accumulation of auranofin in white adipose tissues lowers leptin levels and exerts anti-diabetic effects
Ontology highlight
ABSTRACT: Low-grade, sustained inflammation in white adipose tissue (WAT) characterizes obesity and frequently coincides with insulin resistance and type 2 diabetes (T2D). However, pharmacological targeting of WAT inflammation lacks durable therapeutic effects. Through a computational screen, we identified the FDA-approved rheumatoid arthritis drug auranofin is a putative small molecule for obesity treatment. We discovered that allometrically scaled safe auranofin doses homed to WAT and improved insulin sensitivity in obese wild-type mice. To assess the transcriptional changes underlying the beneficial effects of auranofin, we performed RNA-seq analysis on adipose and liver tissue after 4 weeks of treatment with vehicle or auranofin.
ORGANISM(S): Mus musculus
PROVIDER: GSE202935 | GEO | 2022/10/06
REPOSITORIES: GEO
ACCESS DATA